Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting
“We are delighted to participate in the scientific exchange at this year’s AAD meeting,” said
Title: ARQ-151, Roflumilast Cream, Significantly Improves Chronic Plaque Psoriasis in Phase 2b Study
Session: S027 -
In addition, results from the Phase 1/2a study of topical roflumilast cream in chronic plaque psoriasis have been accepted for an e-poster presentation.
Title: ARQ-151, Roflumilast Cream, Improved Psoriasis in Phase 2a Study
Abstract/poster number: 15309
Date: ePosters will be presented
About Topical Roflumilast Cream (ARQ-151)
Topical roflumilast cream (ARQ-151) is a topical cream formulation containing roflumilast, a PDE4 inhibitor, that Arcutis is developing to treat plaque psoriasis, including intertriginous psoriasis, and atopic dermatitis. PDE4 is an intracellular enzyme that regulates pro-inflammatory and anti-inflammatory cytokine production and cell proliferation. Roflumilast was approved by the FDA for systemic treatment to reduce risk of exacerbation of chronic obstructive pulmonary disease (COPD) in 2011, and has shown greater potency based on IC50 values (a non-clinical measure of a drug's potency) than other PDE4 inhibitors.
About Arcutis - Bioscience, applied to the skin.
Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing three novel compounds (topical roflumilast cream (ARQ-151), topical roflumilast foam (ARQ-154) and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For more information, please visit www.arcutis.com or follow the Company on LinkedIn.
Chief Financial Officer
Investors and Media:
Vice President, Investor Relations & Corporate Communications
805-418-5006, Ext. 740
Source: Arcutis Biotherapeutics, Inc.